CN105451760A - 使用贝那利珠单抗降低哮喘恶化率的方法 - Google Patents

使用贝那利珠单抗降低哮喘恶化率的方法 Download PDF

Info

Publication number
CN105451760A
CN105451760A CN201480043448.XA CN201480043448A CN105451760A CN 105451760 A CN105451760 A CN 105451760A CN 201480043448 A CN201480043448 A CN 201480043448A CN 105451760 A CN105451760 A CN 105451760A
Authority
CN
China
Prior art keywords
fab
monoclonal antibody
pearl monoclonal
patient
give
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480043448.XA
Other languages
English (en)
Chinese (zh)
Inventor
C·沃德
L·罗斯科斯
王冰
D·雷布尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Priority to CN202010449434.5A priority Critical patent/CN111588848A/zh
Publication of CN105451760A publication Critical patent/CN105451760A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Bathtubs, Showers, And Their Attachments (AREA)
CN201480043448.XA 2013-08-12 2014-08-07 使用贝那利珠单抗降低哮喘恶化率的方法 Pending CN105451760A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010449434.5A CN111588848A (zh) 2013-08-12 2014-08-07 使用贝那利珠单抗降低哮喘恶化率的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361864944P 2013-08-12 2013-08-12
US61/864,944 2013-08-12
PCT/US2014/050080 WO2015023504A1 (en) 2013-08-12 2014-08-07 Methods for reducing exacerbation rates of asthma using benralizumab

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010449434.5A Division CN111588848A (zh) 2013-08-12 2014-08-07 使用贝那利珠单抗降低哮喘恶化率的方法

Publications (1)

Publication Number Publication Date
CN105451760A true CN105451760A (zh) 2016-03-30

Family

ID=52448837

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480043448.XA Pending CN105451760A (zh) 2013-08-12 2014-08-07 使用贝那利珠单抗降低哮喘恶化率的方法
CN202010449434.5A Pending CN111588848A (zh) 2013-08-12 2014-08-07 使用贝那利珠单抗降低哮喘恶化率的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010449434.5A Pending CN111588848A (zh) 2013-08-12 2014-08-07 使用贝那利珠单抗降低哮喘恶化率的方法

Country Status (26)

Country Link
US (2) US9441037B2 (enExample)
EP (1) EP3033101B1 (enExample)
JP (4) JP6746495B2 (enExample)
KR (2) KR20220057637A (enExample)
CN (2) CN105451760A (enExample)
AU (2) AU2014306956B2 (enExample)
BR (1) BR112016002401A8 (enExample)
CA (1) CA2918105C (enExample)
CY (1) CY1122132T1 (enExample)
DK (1) DK3033101T3 (enExample)
ES (1) ES2716906T3 (enExample)
HK (1) HK1221644A1 (enExample)
HR (1) HRP20190405T1 (enExample)
HU (1) HUE042607T2 (enExample)
LT (1) LT3033101T (enExample)
ME (1) ME03348B (enExample)
MX (1) MX368508B (enExample)
PL (1) PL3033101T3 (enExample)
PT (1) PT3033101T (enExample)
RS (1) RS58404B1 (enExample)
RU (1) RU2676333C2 (enExample)
SG (2) SG10202005560UA (enExample)
SI (1) SI3033101T1 (enExample)
SM (1) SMT201900163T1 (enExample)
TR (1) TR201903312T4 (enExample)
WO (1) WO2015023504A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111788223A (zh) * 2017-10-03 2020-10-16 拜奥卡德联合股份公司 抗IL-5Rα的单克隆抗体

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201600484TA (en) 2013-08-12 2016-02-26 Medimmune Llc Methods for improving asthma symptoms using benralizumab
DK3033104T3 (da) * 2013-08-12 2019-06-17 Astrazeneca Ab Fremgangsmåder til forøgelse af forceret eksspiratorisk volumen hos astmatikere ved anvendelse af benralizumab
EP3485902A1 (en) * 2013-10-15 2019-05-22 Astrazeneca AB Methods for treating chronic obstructive pulmonary disease using benralizumab
CA2926089C (en) * 2013-10-24 2022-08-30 Medimmune, Llc Stable, aqueous antibody formulations
EP3092253B1 (en) 2014-01-10 2021-03-17 AnaptysBio, Inc. Antibodies directed against interleukin-33 (il-33)
US10699274B2 (en) 2015-08-24 2020-06-30 Samsung Electronics Co., Ltd. Apparatus and method for secure electronic payment
US10846696B2 (en) 2015-08-24 2020-11-24 Samsung Electronics Co., Ltd. Apparatus and method for trusted execution environment based secure payment transactions
HK1255922A1 (zh) 2015-11-04 2019-09-06 Astrazeneca Ab 二肽基肽酶-4和骨膜素作为嗜酸性粒细胞疾病中嗜酸性粒细胞靶向治疗药物临床反应的预测因子
JP7174492B2 (ja) * 2017-01-04 2022-11-17 ウォルグ ファーマシューティカルズ （ハンジョウ） カンパニー，リミテッド Ｓ－アレスチンペプチドおよびその治療的使用
TW202021983A (zh) * 2018-09-21 2020-06-16 美商安納普提斯生物公司 用於嗜伊紅性氣喘之抗il-33療法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066780A2 (en) * 2011-11-01 2013-05-10 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
AU3672800A (en) 1999-04-09 2000-11-14 Kyowa Hakko Kogyo Co. Ltd. Method for controlling the activity of immunologically functional molecule
WO2001060405A1 (en) 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
EP1688437A4 (en) 2003-10-08 2007-09-26 Kyowa Hakko Kogyo Kk ANTIBODY COMPOSITION SPECIFICALLY BINDING TO IL-5 RECEPTOR
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
ES2558689T3 (es) * 2007-05-14 2016-02-08 Medimmune, Llc Métodos para reducir los niveles de eosinófilos
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
AU2010322066A1 (en) * 2009-11-18 2012-06-21 Medicinova, Inc. Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom
WO2012083132A2 (en) 2010-12-16 2012-06-21 Genentech, Inc. Diagnosis and treatments relating to th2 inhibition
EP2710370A4 (en) 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
SG11201600484TA (en) 2013-08-12 2016-02-26 Medimmune Llc Methods for improving asthma symptoms using benralizumab
DK3033104T3 (da) * 2013-08-12 2019-06-17 Astrazeneca Ab Fremgangsmåder til forøgelse af forceret eksspiratorisk volumen hos astmatikere ved anvendelse af benralizumab

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066780A2 (en) * 2011-11-01 2013-05-10 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111788223A (zh) * 2017-10-03 2020-10-16 拜奥卡德联合股份公司 抗IL-5Rα的单克隆抗体
CN111788223B (zh) * 2017-10-03 2024-08-30 拜奥卡德联合股份公司 抗IL-5Rα的单克隆抗体

Also Published As

Publication number Publication date
SG11201600481UA (en) 2016-02-26
BR112016002401A8 (pt) 2018-06-12
US20170198049A1 (en) 2017-07-13
EP3033101A4 (en) 2017-07-12
RU2016108723A3 (enExample) 2018-06-18
RU2676333C2 (ru) 2018-12-28
MX368508B (es) 2019-10-07
HUE042607T2 (hu) 2019-07-29
CA2918105A1 (en) 2015-02-19
WO2015023504A8 (en) 2015-09-24
CY1122132T1 (el) 2020-11-25
EP3033101A1 (en) 2016-06-22
ES2716906T3 (es) 2019-06-17
KR20160042121A (ko) 2016-04-18
RS58404B1 (sr) 2019-04-30
JP2016527324A (ja) 2016-09-08
JP2020128375A (ja) 2020-08-27
CN111588848A (zh) 2020-08-28
AU2014306956B2 (en) 2019-11-21
LT3033101T (lt) 2019-03-25
PL3033101T3 (pl) 2019-06-28
AU2014306956A1 (en) 2016-02-04
PT3033101T (pt) 2019-04-02
ME03348B (me) 2019-10-20
CA2918105C (en) 2023-02-28
JP6746495B2 (ja) 2020-08-26
SMT201900163T1 (it) 2019-05-10
HRP20190405T1 (hr) 2019-04-19
BR112016002401A2 (pt) 2017-09-12
AU2020201327A1 (en) 2020-03-12
HK1225302B (en) 2017-09-08
WO2015023504A1 (en) 2015-02-19
TR201903312T4 (tr) 2019-04-22
RU2016108723A (ru) 2017-09-19
MX2016001383A (es) 2016-08-03
JP2024129139A (ja) 2024-09-26
DK3033101T3 (en) 2019-04-08
US20150044202A1 (en) 2015-02-12
HK1221644A1 (zh) 2017-06-09
US9441037B2 (en) 2016-09-13
SG10202005560UA (en) 2020-07-29
KR102390714B1 (ko) 2022-04-26
JP2022120009A (ja) 2022-08-17
KR20220057637A (ko) 2022-05-09
SI3033101T1 (sl) 2019-04-30
EP3033101B1 (en) 2018-12-19

Similar Documents

Publication Publication Date Title
US9441037B2 (en) Methods for reducing exacerbation rates of asthma using benralizumab
AU2020202564A1 (en) Methods for improving asthma symptoms using benralizumab
US9441046B2 (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
RU2840902C2 (ru) Способы нормализации симптомов астмы с применением бенрализумаба
HK40064505A (en) Methods for improving asthma symptoms using benralizumab
HK40035226A (en) Methods for reducing exacerbation rates of asthma using benralizumab
HK40013807B (en) Methods for improving asthma symptoms using benralizumab
HK40013807A (en) Methods for improving asthma symptoms using benralizumab
HK1225302A1 (en) Methods for reducing exacerbation rates of asthma using benralizumab
HK1225303B (en) Methods for improving asthma symptoms using benralizumab

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20170215

Address after: Swedish Sodertalje

Applicant after: AstraZeneca AB

Address before: American Maryland

Applicant before: Medimmune Vaccines Inc.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1221644

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160330

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1221644

Country of ref document: HK